Breaking Finance News

A statement released today by Jefferies International about AstraZeneca PLC (LON:AZN) ups the target price to 6,000.00GBX

In a statement issued on 10/13/2016 Jefferies International upped the price target of AstraZeneca PLC (LON:AZN) from 5,800.00GBX to 6,000.00GBX indicating a possible upside of 0.20%.

Only yesterday AstraZeneca PLC (LON:AZN) traded -0.07% lower at 5,010.00GBX. AZN’s 50-day average is 4,994.73GBX and its two hundred day average is 4,473.20GBX. The last stock price close is up 10.59% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. Volume of trade was down over the average, with 1,884,116 shares of AZN changing hands under the typical 2,541,030

Performance Chart

AstraZeneca PLC (LON:AZN)

AstraZeneca PLC has a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a P/E ratio of 28.27 The company’s market cap is currently 0 GBX.

Also covering AstraZeneca PLC's target, a total of 29 equity analysts have released a ratings update on AZN. The one year target is 61.96GBX with four equity analysts rating the company a strong buy, 14 brokers rating the stock a buy, 13 brokers rating the stock a hold, 2 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.

General Information About AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.